Biopharma | 20 May 2026
IGI’s new drug candidate ISB 2301 to target solid tumors
The company intends to file an IND submission by the end of this year and begin clinical studies in 2027
The company intends to file an IND submission by the end of this year and begin clinical studies in 2027
The next-generation proteomics platform powered by Olink™ Explore HT enables simultaneous analysis of thousands of proteins from a single sample
Tecentriq SC reduces treatment administration time by nearly 80 percent and has the potential to lower indirect treatment costs
Ex-US revenue rose sharply by 21% YoY to Rs. 2, 240.4 crore ($254 million); Operational PAT grew 50.3% YoY to Rs. 518.1 crore
Funding to support clinical development, gene therapy pipeline expansion and GMP manufacturing capabilities
Lormalzi is the first and only once-monthly amyloid plaque-targeting therapy with clinical evidence
The two companies will establish a joint Center of Excellence (CoE) in Bengaluru
The biosimilars business generated Rs. 10,431 crore in FY26 revenue, up 16% year-on-year
The company highlights role of integrated genomics and multi-omics research at the Illumina Multiomics Summit India 2026 held in New Delhi and Bengaluru
As per GlobalData, CARsgen’s satri-cel could mark a major breakthrough in solid tumor treatment as competition intensifies
The proposed biosimilar to Keytruda demonstrated pharmacokinetic bioequivalence in a multicountry Phase 1 study involving non-small cell lung cancer patients
The US FDA completed a pre-license inspection of Biocon Biologics’ biosimilars manufacturing site at Biocon Park between April 20 and April 29, 2026
Pharma major reports FY26 revenue of Rs 9,204 crore with 16.6% growth
The private funding rose 38% amid growing international collaborations and CDMO demand
Company plans to appeal against CGST order related to alleged inadmissible input tax credit claims
India’s largest life sciences entrepreneurship competition opens applications for startups, innovators and student teams nationwide
Acquisition of medical equipment distributor aims to strengthen European commercial operations and optimise distribution costs
Compared to a net loss of Rs 12 crore in FY25, the pharma major reported a consolidated turnaround in its financial performance
Strong CDMO growth, improved product mix and operational leverage drive profitability expansion
Collaboration to accelerate mRNA neoantigen therapy development for colorectal and pancreatic cancers using advanced immunology and dark genome insights
Subscribe To Our Newsletter & Stay Updated
